Your Article Summary
Medtronic Starts Enrollment in THRIVE, U.S. Post-Market Study of the Talent Thoracic Stent Graft
Medtronic, 04/28/09
Medtronic, Inc. reported the start of THRIVE1, the company's U.S. post-market clinical study of its Talent Thoracic Stent Graft for the endovascular repair of thoracic aortic aneurysms. An aortic aneurysm is a dangerous bulge or weakness in the body's main artery. Untreated, aortic aneurysms can burst, commonly resulting in death due to extensive internal bleeding. Thoracic aortic aneurysms affect nearly 10 of every 100,000 elderly people in the United States.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09
Article Search
Sponsor


See Latest Articles


